Virtual Conference

K Ramalingam

Dr. Rai Memorial Health Center, Cancer Research and Treatment, India

Title: Minimize harms maximize benefits for cancer cure


The basic etiological bottom line for Cancer manifestation is the alterations in genes and chromosomes, at discrete regions which have been designated as oncogenes. The disease in its journey towards full bloom, crosses four stages, out of which the first two stages have been declared as curable while the last 3rd and 4th stages of metastasis are incurable by the existing orthodoxic therapies completely. No doubt, chemotherapy by employing cytotoxic drugs kills 85% of malignant cells. The surgery helps to remove the tumors of considerably larger size. Radiation helps to destroy both localized malignant cells in the tumor foci as well as the fallout cells after surgery and those in systemic circulation. All these conventional strategies of cancer treatments are invariably endowed with intolerable side effects which are harmful to the patients. The differential survival periods after the above interventional therapies are documented evidence towards the existence of cancer cells in oblivion. Drugging the patient by prescription strategies of 3 or 4 times a day have been branded recently as obsolete by FDA (USA). The biochemical processes and genetic profiles of cancer are kept at bay in silence to be revoked later.

One specific instance in which the agouti (mice) gene besides its original phenotypic expression, pleiotropically manifest cancer was ‘put off’ by Vitamin-B12, folic acid and choline. The above episode unraveled the secret that the genes inducing cancers are not indelible blueprints but could be altered by supplements. Apart from vitamins, innumerable herbal compounds can be anti-cancerous and can remain as a supportive therapy, as adjuvants alongside the conventional strategies endowed with more side effects, harmful to the patients. The following jargon viz., Minimize the harms Maximize the benefits can bring cure to Breast Cancer until the lifetime of individuals.


K. Ramalingam has completed his Ph.D in Zoology/Toxicology in 1981. He was awarded D.Sc., in 2017. He has held the position of Asst. Professor; Professor; H.O.D., and affiliated Ph.D research supervisor during his service in the TamilNadu Education Department. In 2008, he joined Mediclone Biotech Pvt Ltd., as Senior Scientist till 2011. He has served as Dean Research and H.O.D Marine Biotech in AMET University, Chennai for 3 yrs (2014-2016). He is an IEC Member in Dr. Rai Memorial Health Center, Cancer Treatment and Research.